白三烯受体拮抗剂联合鼻用激素治疗变应性鼻炎的系统评价

冯韶燕; 樊韵平; 李磊; 陈默; 王运中; 许庚; 李华斌

doi:10.13201/j.issn.1001-1781.2015.03.004

白三烯受体拮抗剂联合鼻用激素治疗变应性鼻炎的系统评价

- 1 上海交通大学医学院附属新华医院耳鼻咽喉头颈外科(上海, 200092);
- 2 广东中山大学附属第五医院耳鼻咽喉科;
- 3 中山大学附属第一医院耳鼻咽喉医院
基金项目:
国家科技支撑计划项目(No:2014BAI07B00)

国家自然科学基金项目(No:81271056)

详细信息

通讯作者: 李华斌,E-mail:noseli@163.com

中图分类号: R765.21

收稿日期: 2014-11-18

Leukotriene receptor antagonist as add-on therapy to intranasal corticosteroids in the treatment of allergic rhinitis:a systematic review

- 1 Department of Otolaryngology Head and Neck Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200092, China;
- 2 Department of Otolaryngology, the Fifth Affiliated Hospital of Sun Yat-sen University;
- 3 Allergy and Cancer Center, Otorhinolarygology Hospital, the First Affiliated Hospital of Sun Yat-sen University

More Information

Corresponding author: LI Huabin, E-mail: noseli@163.com

Received Date: 18 November 2014

摘要

摘要: 目的:系统评价白三烯受体拮抗剂(LTRA)联合鼻用激素治疗变应性鼻炎(AR)的临床疗效,为优化AR药物治疗方案提供循证依据。方法:计算机检索OVID、PubMed、EMBASE和Cochrane Library、中国学术期刊全文数据库(CNKI)、万方数据库。检索时限截至2014年5月,纳入有关LTRA联用鼻用激素治疗AR的随机对照实验,经2位研究者独立进行文献筛选、资料提取和方法学质量评价后,采用RevMan 5.1软件进行荟萃(Meta)分析。结果:经检索和筛选,共纳入5个随机对照试验。Meta分析结果显示:鼻用激素加LTRA组的鼻症状总分及流涕、喷嚏症状评分较单用鼻用激素组明显降低[WMD=-4.49,95% CI (-4.95~-4.03),P<0.01;WMD=-0.43,95% CI (-0.78~-0.07),P<0.05;WMD=-0.10,95% CI (-0.16~-0.04),P<0.01];而鼻用激素加LTRA组的鼻塞、鼻痒评分及RQLQ评分与单用鼻用激素组差异无统计学意义[WMD=0.01,95% CI (-0.06~0.08),P＞0.05;WMD=-0.15,95% CI (-0.43~0.13),P＞0.05; WMD=-15.19, 95% CI(-55.37~25.00),P＞0.05]。结论:根据目前Meta分析的研究结果,初步认为LTRA联用鼻用激素在治疗AR方面疗效优于单用鼻用激素,且安全性良好,但仍需要今后大样本、多中心的随机对照试验进一步证实。
- 鼻炎 /
- 变应性 /
- 白三烯受体拮抗剂 /
- 鼻用激素 /
- 疗效 /
- Meta分析
Abstract: Objective: To systematically evaluate the efficacy and safety of leukotriene receptor antagonist (LTRA) combined intranasal corticosteroids in the treatment of allergic rhinitis (AR).Method: The randomized controlled trials (RCT) about the combined therapy of LTRA and nasal corticosteroids from January 1985 to May 2014 were searched in OVID,PubMed,EMBASE,CNKI,WanFang Data,and Cochrane Library. Two reviewers independently screened the literatures, extracted the data, and evaluated the methodological quality.Then meta-analyses were conducted by using RevMan 5.1 software.Result: A total of 5 RCTs were included upon literature search. The results of meta-analyses showed that the efficacy of nasal corticosteroids plus LTRA was superior to nasal corticosteroids alone in total nasal symptom scores and individual nasal symptom scores (rhinorrhea, sneezing) [WMD=-4.49, 95% CI(-4.95--4.03), P<0.01; WMD=-0.43, 95% CI(-0.78--0.07), P<0.05; WMD=-0.10, 95% CI( -0.16--0.04), P<0.01], with significant differences. However, comparing the subgroup treated with nasal corticosteroids combined LTRA against the subgroup treated with nasal corticosteroids alone, we found no significant differences for RQLQ score and for individual nasal symptom scores (nasal blockage, nasal itching) [WMD=-15.19, 95% CI(-55.37-25.00), P＞0.05; WMD=0.01, 95% CI(-0.06-0.08), P＞0.05; WMD=-0.15, 95% CI(-0.43-0.13), P＞0.05]. Conclusion: Based on limited evidence, we preliminary concluded the combined therapy of nasal corticosteroids and LTRA was more effective than nasal corticosteroids alone in the management of AR. Further large-scale, well-designed RCTs were still required to validate the add-on efficacy of LTRA for AR patients.
- rhinitis /
- allergic /
- leukotriene receptor antagonist /
- intranasal corticosteroids /
- efficacy /
- Meta-analysis

HTML全文

参考文献(20)

[1]	MCMENAMIN P. Costs of hay fever in the United States in 1990[J]. Ann Allergy,1994,73:35-39.
[2]	RAY N F, BARANIUK J N, THAMER M, et al. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses[J]. J Allergy Clin Immunol,1999,103:401-407.
[3]	LAGOS J A, MARSHALL G D. Montelukast in the management of allergic rhinitis[J]. Ther Clin Risk Manag, 2007,3:327-332.
[4]	TOPUZ B, OGMEN G G. Montelukast as an adjuvant to mainstay therapies in patients with seasonal allergic rhinitis[J]. Clin Exp Allergy,2003,33:823-826.
[5]	JOOS S, MIKSCH A, SZECSENYI J, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma:a systematic review[J].Thorax, 2008,63:453-462.
[6]	GROSSMAN J. One airway, one disease[J]. Chest,1997,111:11S-16S.
[7]	JUNI P, ALTMAN D G, EGGER M. Systematic reviews in health care:Assessing the quality of controlled clinical trials[J]. BMJ, 2001, 323:42-46.
[8]	DI LORENZO G, PACOR M L, PELLITTERI M E, et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis[J]. Clin Exp Allergy,2004,34:259-267.
[9]	PINAR E, ERYIGIT O, ONCEL S, et al. Efficacy of nasal corticosteroids alone or combined with antihistamines or montelukast in treatment of allergic rhinitis[J]. Auris Nasus Larynx, 2008,35:61-66.
[10]	MODGILL V, BADYAL D K, VERGHESE A. Efficacy and safety of montelukast add-on therapy in allergic rhinitis[J].Methods Find Exp Clin Pharmacol,2010,32:669-674.
[11]	ESTEITIE R, DETINEO M, NACLERIO R M, et al. Effect of the addition of montelukast to fluticasone propionate for the treatment of perennial allergic rhinitis[J]. Ann Allergy Asthma Immunol,2010,105:155-161.
[12]	GOH B S, ISMAIL M I, HUSAIN S. Quality of life assessment in patients with moderate to severe allergic rhinitis treated with montelukast and/or intranasal steroids:a randomised, double-blind, placebo-controlled study[J]. J Laryngol Otol, 2014, 128:242-248.
[13]	KNANI J, CAMPBELL A, ENANDER I, et al. Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis[J]. J Allergy Clin Immunol,1992, 90:880-889.
[14]	KOJIMA T, ASAKURA K. A study of chemical mediators in patients with allergic rhinitis:3. Release of histamine and leukotrienes from in vitro nasal mucosa[J]. Nippon Jibiinkoka Gakkai Kaiho,1991, 94:587-593.
[15]	WANG D, CLEMENT P, SMITZ J, et al. Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after nasal allergen challenge and during natural allergen exposure[J]. Int Arch Allergy Immunol,1995, 106:278-285.
[16]	SKONER D P, LEE L, DOYLE W J, et al. Nasal physiology and inflammatory mediators during natural pollen exposure[J]. Ann Allergy,1990, 65:206-210.
[17]	VAN HOECKE H, VANDENBULCKE L, VAN CAUWENBERGE P. Histamine and leukotriene receptor antagonism in the treatment of allergic rhinitis:an update[J]. Drugs, 2007, 67:2717-2726.
[18]	NATHAN R A. Pharmacotherapy for allergic rhinitis:a critical review of leukotriene receptor antagonists compared with other treatments[J]. Ann Allergy Asthma Immunol, 2003,90:182-190.
[19]	WILSON A M, O'BYME P M, PARAMESWARAN K. Leukotriene receptor antagonists for allergic rhinitis:a systematic review and meta-analysis[J]. Am J Med, 2004,116:338-344.
[20]	GRAINGER J, DRAKE-LEE A. Montelukast in allergic rhinitis:a systematic review and meta-analysis[J]. Clin Otolaryngol,2006,31:360-367.